PVLA Stock Forecast & Price Target

Palvella Therapeutics is attractive because its lead asset, QTORIN 3.9% rapamycin anhydrous gel, has already de-risked the core mLM thesis by meeting all SELVA primary and prespecified secondary endpoints, with the rolling NDA completed on Aug 31 and a possible priority review decision expected in 60 days. The company also benefits from a defensible niche: mLM and cVM have no FDA-approved therapies, while prior Phase 2 cVM data were positive and support a Phase 3 start in 4Q26, suggesting multiple shots on goal within a single-segment rare disease platform. Financially, the setup looks scalable rather than speculative, with a planned ~40-rep launch force targeting ~400 centers that cover about half the market, defendable pricing around ~$170K net, and a management team strengthened by key commercial hires.

Palvella Therapeutics is burdened by substantial clinical and regulatory uncertainty, as the FDA has already signaled endpoint and bioavailability concerns for mLM, while cVM evidence remains thin after an open-label 16-patient study with no prespecified primary endpoint and declined Breakthrough Therapy designation in July. Its commercial case is also fragile because the company has never generated product revenue, relies on a novel and unproven QTORIN platform, and faces cheaper off-label sirolimus options, uncertain durability, and possible competition from pipeline assets. Financially, it held $250.6M in cash and short-term investments at June 30, 2026, yet still guides to only at least 12 months of runway, with negative free cash flow expected through 2028 and additional dilution likely.